Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
This PHASE1/PHASE2 trial investigates Multiple Myeloma and is currently completed. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Millennium Pharmaceuticals, Inc.
- PETHEMA Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , León, Spain , Madrid, Spain , Murcia, Spain , Oviedo, Spain , Palma de Mallorca, Spain , Pamplona, Spain , Salamanca, Spain , Santa Cruz de Tenerife, Spain , Segovia, Spain and 2 more locations